Overview

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-18
Target enrollment:
Participant gender:
Summary
This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease.
Phase:
PHASE1
Details
Lead Sponsor:
GlaxoSmithKline